IVUS CHIP
Intravascular Ultrasound-Guided vs Angiography-Guided PCI in Complex Coronary Lesions
Presented by Roberto Diletti — Erasmus Medical Center
Subspecialty: Interventional
Published in NEJM
Key Result
IVUS-guided PCI in complex coronary lesions — results from a landmark European multicenter trial presented at ACC.26 and published in NEJM.
What did this trial find?
The IVUS CHIP trial is a European multicenter randomized controlled trial comparing IVUS-guided versus angiography-guided PCI in patients with complex coronary lesions, led by Roberto Diletti from Erasmus Medical Center. Results were presented at ACC.26 and published in NEJM. The source material provided contains no direct quotes or expert commentary specifically about the IVUS CHIP trial — all available quotes pertain to other IVUS-related trials (IVUS-ACS, RENOVATE-COMPLEX-PCI, ULTIMATE, VIDIO, and peripheral vascular IVUS studies).
Why does this trial matter?
No verifiable quotes about the IVUS CHIP trial were found in the source material. The trial appears to have been very recently presented at ACC.26 and published in NEJM, but all source material retrieved pertains to other IVUS-related trials (IVUS-ACS, RENOVATE-COMPLEX-PCI, ULTIMATE, peripheral IVUS studies). The study design paper was found in Lirias but contained no quotable expert commentary. Coverage and expert reaction specific to IVUS CHIP is not yet available in the provided sources.
Study Design
Randomized, controlled, multicenter international trial across 7 European countries
Clinical Implications
Addresses whether IVUS guidance improves outcomes over standard angiography in the most complex PCI cases, with potential to change how interventional cardiologists approach high-risk coronary procedures.
Abstract
The IVUS-CHIP trial is a randomized controlled, multicenter, international study comparing IVUS-guided versus angiography-guided PCI in patients with complex coronary lesions. Led by Roberto Diletti from Erasmus Medical Center, the trial enrolled patients across approximately 40 hospitals in 7 European countries, sponsored by ECRI with support from Boston Scientific. Results were presented as a late-breaking trial at ACC.26 and published in NEJM.